RxSight (RXST) Insider Warner Robert Keith Buys 37,037 Shares

Board Members and Executives Show Collective Support

Warner Robert Keith increased his position in RxSight, Inc. (RXST) on June 17, 2026, by acquiring 37,037 shares of the company's stock. This transaction was not an isolated event; it was part of a significant wave of insider activity where multiple leaders at the firm bolstered their stakes on the same day. These purchases were made directly in the open market and were not part of any pre-arranged Rule 10b5-1 trading plans, which are often used by insiders to schedule trades in advance.

The scale of this buying is notable for a company of RxSight's size. By adding 37,037 shares, Keith joined a group of five other insiders who each bought the exact same number of shares, while one additional insider purchased more than 30,000 shares. This level of synchronized buying often draws the attention of investors because it shows a unified front among those who manage the business.

RxSight Stock Performance Context

On Friday, shares of RxSight were trading at $4.73. This price level is significant because it sits just above the 52-week low of $4.48 and is a steep drop from the 52-week high of $13.22. The stock has been facing downward pressure, evidenced by the fact that it is currently priced below both its 50-day moving average of $6.09 and its 200-day moving average of $7.31. When insiders buy shares during a period of price weakness, it can sometimes be seen as their attempt to capitalize on what they perceive as an undervalued stock.

Broad Insider Activity on June 17

Joining Warner Robert Keith in the market on June 17, 2026, were several other key figures at RxSight. Julie Andrews, Tamara Fountain, Corley Jesse Anderson, Shweta Maniar, and Link William Phd each purchased 37,037 shares. Raymond Cohen also participated in the buying spree, acquiring 30,864 shares. None of these transactions involved a pre-set trading plan. This cluster of activity is often viewed as a strong signal of confidence from the board and executive team regarding the company's future prospects.

Financial Health and Upcoming Earnings

RxSight reported revenue of $127.58 million for its most recent period, with a slight revenue growth of 0.3%. The company is currently in a growth phase and is not yet profitable, which is why it does not have a meaningful P/E ratio. Its net margin stands at -36.8%, and it has a return on equity of -17.3%. Despite these losses, the company maintains a current ratio of 4.07, indicating it has a healthy amount of short-term assets compared to its liabilities. Shareholders are looking toward November 4, 2026, when the company is expected to release its next financial update.

Analysts Set New Price Targets

Wall Street has a mixed but generally cautious view of RxSight. On September 22, 2026, Jefferies maintained a Hold rating and lowered its price target from $6.50 to $5.75. B of A Securities also maintained an Underperform rating on that same day, cutting its target to $5.50. Earlier in the summer, Needham reiterated a Buy rating with a much higher price target of $11.00 on July 7, 2026. Currently, the consensus among eight analysts is a Hold, with an average price target of $7.79, which still suggests potential upside from the recent trading price.

About RxSight, Inc.

RxSight is a medical technology company that specializes in improving vision for people undergoing cataract surgery. Based in Aliso Viejo, California, the company produces a unique light-adjustable lens that doctors can fine-tune after it has already been implanted in a patient's eye. By using a specialized light delivery device, surgeons can adjust the shape of the lens to provide the most accurate vision possible, reducing the need for glasses after the procedure. The company was formerly known as Calhoun Vision before rebranding in 2017.

Investors should keep in mind that insider trades and 13F filings are backward-looking reports. They show what happened on a specific date in the past and may not reflect the current opinions or future intentions of the people involved. These reports are just one piece of the puzzle when evaluating a company's financial situation.